Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer
We studied genomic alterations in 19 inflammatory breast cancer (IBC) patients with advanced disease using samples of tissue and paired blood serum or plasma (cell-free DNA, cfDNA) by targeted next generation sequencing (NGS). At diagnosis, the disease was triple negative (TN) in eleven patients (57.8%), ER+ Her2- IBC in six patients (31.6%), ER+ Her2+ IBC in one patient (5.3%), and ER- Her2+ IBC in one other patient (5.3%). Pathogenic or likely pathogenic variants were frequently detected in TP53 (47.3%), PMS2 (26.3%), MRE11 (26.3%), RB1 (10.5%), BRCA1 (10.5%), PTEN (10.5%) and AR (10.5%); other affected genes included PMS1, KMT2C, BRCA2, PALB2, MUTYH, MEN1, MSH2, CHEK2, NCOR1, PIK3CA, ESR1 and MAP2K4. In 15 of the 19 patients in which tissue and paired blood were collected at the same time point, 80% of the variants detected in tissue were also detected in the paired cfDNA. Higher concordance between tissue and cfDNA was found for variants with higher allele fraction in tissue (AFtissue ≥ 5%). Furthermore, 86% of the variants detected in cfDNA were also detected in paired tissue. Our study suggests that the genetic profile measured in blood cfDNA is complementary to that of tumor tissue in IBC patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 21(2020), 4 vom: 14. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Winn, Jennifer S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.11.2020 Date Revised 13.08.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms21041290 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306689375 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306689375 | ||
| 003 | DE-627 | ||
| 005 | 20231225123927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms21041290 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1022.xml |
| 035 | |a (DE-627)NLM306689375 | ||
| 035 | |a (NLM)32075053 | ||
| 035 | |a (PII)E1290 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Winn, Jennifer S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.11.2020 | ||
| 500 | |a Date Revised 13.08.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We studied genomic alterations in 19 inflammatory breast cancer (IBC) patients with advanced disease using samples of tissue and paired blood serum or plasma (cell-free DNA, cfDNA) by targeted next generation sequencing (NGS). At diagnosis, the disease was triple negative (TN) in eleven patients (57.8%), ER+ Her2- IBC in six patients (31.6%), ER+ Her2+ IBC in one patient (5.3%), and ER- Her2+ IBC in one other patient (5.3%). Pathogenic or likely pathogenic variants were frequently detected in TP53 (47.3%), PMS2 (26.3%), MRE11 (26.3%), RB1 (10.5%), BRCA1 (10.5%), PTEN (10.5%) and AR (10.5%); other affected genes included PMS1, KMT2C, BRCA2, PALB2, MUTYH, MEN1, MSH2, CHEK2, NCOR1, PIK3CA, ESR1 and MAP2K4. In 15 of the 19 patients in which tissue and paired blood were collected at the same time point, 80% of the variants detected in tissue were also detected in the paired cfDNA. Higher concordance between tissue and cfDNA was found for variants with higher allele fraction in tissue (AFtissue ≥ 5%). Furthermore, 86% of the variants detected in cfDNA were also detected in paired tissue. Our study suggests that the genetic profile measured in blood cfDNA is complementary to that of tumor tissue in IBC patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cell-free DNA (cfDNA) | |
| 650 | 4 | |a inflammatory breast cancer (IBC) | |
| 650 | 4 | |a next generation sequencing (NGS) | |
| 650 | 7 | |a BRCA2 Protein |2 NLM | |
| 650 | 7 | |a BRCA2 protein, human |2 NLM | |
| 650 | 7 | |a Cell-Free Nucleic Acids |2 NLM | |
| 650 | 7 | |a TP53 protein, human |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a PMS2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.6.1.- |2 NLM | |
| 650 | 7 | |a Mismatch Repair Endonuclease PMS2 |2 NLM | |
| 650 | 7 | |a EC 3.6.1.3 |2 NLM | |
| 700 | 1 | |a Hasse, Zachary |e verfasserin |4 aut | |
| 700 | 1 | |a Slifker, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Pei, Jianming |e verfasserin |4 aut | |
| 700 | 1 | |a Arisi-Fernandez, Sebastian M |e verfasserin |4 aut | |
| 700 | 1 | |a Talarchek, Jacqueline N |e verfasserin |4 aut | |
| 700 | 1 | |a Obeid, Elias |e verfasserin |4 aut | |
| 700 | 1 | |a Baldwin, Donald A |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Yulan |e verfasserin |4 aut | |
| 700 | 1 | |a Ross, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Cristofanilli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Alpaugh, R Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez, Sandra V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 21(2020), 4 vom: 14. Feb. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:4 |g day:14 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms21041290 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 4 |b 14 |c 02 | ||